Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

LA JOLLA, Calif., Nov. 14 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced financial results for the third quarter ended September 30, 2007. For the three-month period, the Company posted revenue of $2.5 million and a net loss of $6.8 million. Cash and cash equivalents totaled $39.7 million at September 30, 2007.

"Last quarter we continued to advance our three priority product candidates and most notably, after the quarter ended, we announced positive results from our Phase IIb clinical trial evaluating our lead compound, tezampanel, in acute migraine," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "We now have two migraine studies in which tezampanel demonstrated statistically significant improvement on the primary end point of pain response at two hours post-dose compared to placebo. These Phase IIb results further establish the efficacy and safety of tezampanel and we are pleased to be advancing tezampanel into later-stage clinical development."

Highlights:

-- In October 2007, announced that tezampanel met the primary endpoint at

the 40 mg dose in a 306-patient, Phase IIb clinical trial for the

treatment of a single, acute migraine attack. Two other doses, 70 mg

and 100 mg, were evaluated and also demonstrated effects across a

number of pain measurements although neither dose reached statistical

significance on the primary endpoint. In this trial, tezampanel was

well-tolerated and there were no serious or medically important

adverse events reported.

-- Initiated a Phase I multiple-dose clinical trial of tezampanel to

evaluate the safety, tolerability
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):Princeton scientists find way to catalog all that goes wrong in a cancer cell 2Vermicompost from pig manure grows healthy hibiscus 2New biological route for swine flu to human infections 2New biological route for swine flu to human infections 3Kristi Yamaguchi Joins the American Lung Association of the Central States to Encourage Annual Influenza Vaccination to Help Americans Prepare for Flu 58496 1Kristi Yamaguchi Joins the American Lung Association of the Central States to Encourage Annual Influenza Vaccination to Help Americans Prepare for Flu 58496 2Kristi Yamaguchi Joins the American Lung Association of the Central States to Encourage Annual Influenza Vaccination to Help Americans Prepare for Flu 58496 3Kristi Yamaguchi Joins the American Lung Association of the Central States to Encourage Annual Influenza Vaccination to Help Americans Prepare for Flu 58496 4Kristi Yamaguchi Joins the American Lung Association of the Central States to Encourage Annual Influenza Vaccination to Help Americans Prepare for Flu 58496 5Pelosi and Hoyer Remarks at Press Availability Following Leadership Meeting 58494 1Pelosi and Hoyer Remarks at Press Availability Following Leadership Meeting 58494 2Pelosi and Hoyer Remarks at Press Availability Following Leadership Meeting 58494 3Pelosi and Hoyer Remarks at Press Availability Following Leadership Meeting 58494 4Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6 2009 58489 1